Recreational phenethylamine poisonings reported to a French poison control center.
Gaël Le Roux, Chloé Bruneau, Benedicte Lelievre, Marie Bretaudeau Deguigne, Alain Turcant, Patrick Harry, David Boels
Drug and Alcohol Dependence September 1, 2015 DOI: 10.1016/j.drugalcdep.2015.05.048 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective case series Case report Peer reviewed |
|---|---|
| Sample size | 105 |
| Population | Patients with phenethylamine poisoning reported to the Poison Control Center of Angers, France, from January 2007 to December 2013 |
| Duration | January 2007 to December 2013 |
| Measures | Poison Severity Score |
| Keywords | Amphetamines Designer drugs Phenethylamines Poison control center Poisoning |
| Key findings | Among 105 phenethylamine poisoning cases, MDMA, amphetamine, and methamphetamine were most commonly implicated. Severe or fatal poisoning occurred in 13% of cases, 12.4% required intensive care, and 5 patients died, indicating that phenethylamine poisoning can be severe even in young, healthy individuals. |
Abstract
Over the last decade, use of phenethylamines has become increasingly prevalent. This study aimed to describe typical aspects of phenethylamine poisoning in order to better inform patient care. Phenethylamine poisoning cases reported to the Poison Control Center of Angers, France, from January, 2007 to December, 2013 were examined. Clinical findings were examined in 105 patients, including phenethylamine used, symptoms and final outcome. Patients were predominantly male (80%), with mean age 26±8 years. MDMA (38%), amphetamine (18%) and methamphetamine (14%) were the most commonly reported. Synthetic cathinones (10%) and the 2C series (7%) were also found. Substances most commonly associated with phenethylamine poisoning were cannabis (27%), ethanol (20%) and cocaine (9%). The most frequently reported symptoms included anxiety and hallucinations (49%), mydriasis and headache (41%), tachycardia (40%) and hypertension (15%). Complications such as seizures (7%), cardiac arrest (5%), toxic myocarditis (1%) and hemorrhagic stroke (1%) were also observed. Of the cases, the Poison Severity Score was: null or low, 66%, moderate, 21%, severe or fatal, 13%. Of the patients, 77% received hospital care and 12.4% were admitted to an intensive care unit. Analytical confirmations were obtained for all severe cases. While 93% of patients recovered, there were 5 deaths and 2 patients presented with neurological sequelae. Phenethylamine poisonings may be severe in young and healthy individuals. Physicians, toxicologists and analysts should be aware of new phenethylamine consumption trends in order to inform management of patient care and to contribute to a more responsive drug policy.
Citations in the library
Cited by 6
- Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants Frontiers in Neuroscience April 19, 2016
- Acute Effects of the Psychedelic Phenethylamine 25I-NBOMe in C57BL/6J Male Mice. International Journal of Molecular Sciences March 20, 2025
- Metabolism study of two phenethylamine - derived new psychoactive substances using in silico, in vivo, and in vitro approaches. Archives of Toxicology March 10, 2025
- Designer Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System. ACS Chemical Neuroscience August 2, 2023
- Differential role of dose and environment in initiating and intensifying neurotoxicity caused by MDMA in rats BMC Pharmacology and Toxicology August 5, 2019
and 1 more in the library
Cites 7
- Clinical toxicology of newer recreational drugs Clinical Toxicology October 1, 2011
- Designer Drugs on the Internet: A Phenomenon Out-of-Control? The Emergence of Hallucinogenic Drug Bromo-Dragonfly Current reviews in clinical and experimental pharmacology May 1, 2011
- Acute medical problems due to Ecstasy use. Case-series of emergency department visits. October 29, 2005
- The Neuropsychopharmacology and Toxicology of 3,4‐methylenedioxy‐N‐ethyl‐amphetamine (MDEA) CNS Drug Reviews June 1, 2004
- Fluorine in psychedelic phenethylamines Drug Testing and Analysis February 28, 2012
and 2 more in the library